Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
No apparent effect of naproxen on CSF markers of innate immune activation.
Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group. Meyer PF, et al. Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun. Ann Clin Transl Neurol. 2019. PMID: 31211178 Free PMC article. Clinical Trial.
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.
Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Among authors: meyer pf. JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. JAMA Netw Open. 2020. PMID: 32031648 Free article.
Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.
Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Among authors: meyer pf. Neuroimage. 2021 Feb 4;231:117832. doi: 10.1016/j.neuroimage.2021.117832. Online ahead of print. Neuroimage. 2021. PMID: 33549747 Free article.
34 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page